TN2011000222A1 - Melanocortin receptor agonists - Google Patents

Melanocortin receptor agonists

Info

Publication number: TN2011000222A1
Authority: TN; Tunisia
Prior art keywords: melanocortin receptor; receptor agonists; agonistic; isomer; melanocortin
Prior art date: 2008-11-12

Application number

TN2011000222A

Other languages

English (en)

Inventor

Koo Lee

Sang Dae Lee

Sang Pil Moon

In Ae Ahn

Sung Pil Choi

Hyun Ho Lee

Dong Sup Shim

Soo Yong Chung

Hyun Min Lee

Original Assignee

Lg Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-12

Filing date

2011-05-06

Publication date

2012-12-17

2011-05-06 Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd

2012-12-17 Publication of TN2011000222A1 publication Critical patent/TN2011000222A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)

TN2011000222A 2008-11-12 2011-05-06 Melanocortin receptor agonists TN2011000222A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20080112403		2008-11-12
PCT/KR2009/006568 WO2010056022A2 (fr)	2008-11-12	2009-11-10	Antagonistes de récepteur de mélanocortine

Publications (1)

Publication Number	Publication Date
TN2011000222A1 true TN2011000222A1 (en)	2012-12-17

Family

ID=42165801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000222A TN2011000222A1 (en)	2008-11-12	2011-05-06	Melanocortin receptor agonists

Country Status (26)

Country	Link
US (4)	US8288386B2 (fr)
EP (1)	EP2350060B1 (fr)
JP (1)	JP5399506B2 (fr)
KR (1)	KR101141976B1 (fr)
CN (1)	CN102282141B (fr)
AR (1)	AR074109A1 (fr)
AU (1)	AU2009314827B2 (fr)
BR (1)	BRPI0921063B8 (fr)
CA (1)	CA2742248C (fr)
CL (1)	CL2011001073A1 (fr)
CO (1)	CO6362006A2 (fr)
CR (1)	CR20110250A (fr)
EA (1)	EA019146B1 (fr)
EC (1)	ECSP11011026A (fr)
GE (1)	GEP20135850B (fr)
IL (1)	IL212468A0 (fr)
MA (1)	MA32774B1 (fr)
MX (1)	MX2011004583A (fr)
NZ (1)	NZ592512A (fr)
PE (1)	PE20110684A1 (fr)
TN (1)	TN2011000222A1 (fr)
TW (1)	TWI389903B (fr)
UA (1)	UA99555C2 (fr)
UY (1)	UY32238A (fr)
WO (1)	WO2010056022A2 (fr)
ZA (1)	ZA201103154B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA99555C2 (en) *	2008-11-12	2012-08-27	Элджи Лайф Саенсез Лтд.	Melanocortin receptor agonists
CA2825098C (fr)	2011-01-27	2020-03-10	Universite De Montreal	Pyrazolopyridine et derives de pyrazolopyrimidine en tant que modulateurs du recepteur de la melanocortine-4
EP3539551B1 (fr)	2011-12-29	2021-10-06	Rhythm Pharmaceuticals, Inc.	Procédé de traitement de troubles associés au récepteur de la mélanocortine-4 dans des porteurs hétérozygotes
JP6235560B2 (ja)	2012-04-25	2017-11-22	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	（３，４−ジクロロ−フェニル）−（（ｓ）−３−プロピル−ピロリジン−３−イル）−メタノン塩酸塩及び製造方法
CN103420981A (zh) *	2012-05-21	2013-12-04	中国医学科学院药物研究所	含有取代吡咯烷基的硫代吗啉类化合物
MX2018003983A (es)	2015-09-30	2018-11-09	Rhythm Pharmaceuticals Inc	Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
AU2019249255A1 (en)	2018-04-06	2020-11-05	Alastair GARFIELD	Compositions for treating kidney disease
MX2021014074A (es)	2019-11-07	2021-12-10	Lg Chemical Ltd	Agonistas de receptor de melanocortina-4.
KR102672625B1 (ko) *	2020-10-29	2024-06-07	주식회사 엘지화학	멜라노코르틴 수용체 작용제 화합물의 결정형 ⅱ 및 이의 제조방법
US20240010633A1 (en)	2020-10-29	2024-01-11	Lg Chem, Ltd.	Crystalline form iv of melanocortin receptor agonist compound and preparation method therefor
US20250179016A1 (en) *	2020-10-29	2025-06-05	Lg Chem, Ltd.	Amorphous melanocortin-4 receptor agonist
JP2023548165A (ja) *	2020-10-29	2023-11-15	エルジー・ケム・リミテッド	メラノコルチン受容体アゴニスト化合物の結晶形ｉｉｉおよびその製造方法
PE20240048A1 (es)	2020-10-29	2024-01-09	Lg Chemical Ltd	Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma
CN116669742B (zh) *	2020-12-22	2025-08-29	株式会社Lg化学	无定形黑皮质素受体激动剂及其制备方法
TWI832128B (zh) *	2020-12-22	2024-02-11	南韓商Ｌｇ化學股份有限公司	使用作為黑皮質素-4受體選擇性促效劑
CN116669743A (zh) *	2020-12-22	2023-08-29	株式会社Lg化学	黑皮质素受体激动剂化合物的结晶形式i及其制备方法
WO2022139446A1 (fr) *	2020-12-22	2022-06-30	주식회사 엘지화학	Forme cristalline iii de composé agoniste du récepteur de la mélanocortine et procédé de préparation s'y rapportant
EP4249484A4 (fr)	2020-12-22	2024-05-15	Lg Chem, Ltd.	Cristal de type ii d'un composé agoniste du récepteur de la mélanocortine et son procédé de préparation
MX2023008098A (es) *	2021-01-21	2023-07-14	Lg Chemical Ltd	Uso de agonista del receptor de melanocortina-4.
CN116888110A (zh) *	2021-02-26	2023-10-13	株式会社Lg 化学	黑皮质素-4受体激动剂
CN117242064A (zh) *	2021-05-06	2023-12-15	株式会社Lg 化学	黑皮质素受体激动剂化合物的晶型v及其制备方法
EP4317150A4 (fr) *	2021-05-06	2024-10-30	Lg Chem, Ltd.	Forme cristalline vii d'un composé agoniste du récepteur de la mélanocortine et son procédé de préparation
KR102854597B1 (ko)	2021-05-07	2025-09-03	주식회사 엘지화학	멜라노코르틴 수용체 작용제 화합물의 유기산 염의 결정형 ⅳ 및 이의 제조방법
EP4317148A4 (fr)	2021-05-07	2024-09-18	Lg Chem, Ltd.	Cristaux de sulfate de composé agoniste du récepteur de la mélanocortine et leur procédé de production
WO2022235107A1 (fr) *	2021-05-07	2022-11-10	주식회사 엘지화학	Co-cristal de composé agoniste du récepteur de la mélanocortine et de vanilline et son procédé de préparation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6534503B1 (en) *	1998-04-28	2003-03-18	Lion Bioscience Ag	Melanocortin receptor-3 ligands to treat sexual dysfunction
EP1187614A4 (fr)	1999-06-04	2005-06-22	Merck & Co Inc	Piperidines substituees en tant qu'agonistes du recepteur de melanocortine-4
GB0002059D0 (en)	2000-01-28	2000-03-22	Melacure Therapeutics Ab	Novel aromatic amines
JP2003527444A (ja)	2000-03-23	2003-09-16	メルクエンドカムパニーインコーポレーテッド	メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
EP1268449A4 (fr)	2000-03-23	2004-09-15	Merck & Co Inc	Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
GB0019359D0 (en)	2000-08-07	2000-09-27	Melacure Therapeutics Ab	Novel guanidines
JP2004506687A (ja)	2000-08-23	2004-03-04	メルク　エンド　カムパニー　インコーポレーテッド	メラノコルチン受容体作働薬としての置換ピペリジン類
DZ3415A1 (fr)	2000-08-31	2002-03-07	Chiron Corp	Guanidinobenzamides comme mc4-r agonistes.
WO2002059095A1 (fr)	2001-01-23	2002-08-01	Eli Lilly And Company	Agonistes de recepteurs de melanocortine
DE60205727T2 (de)	2001-01-23	2006-06-29	Eli Lilly And Co., Indianapolis	Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors
US7157463B2 (en)	2001-01-23	2007-01-02	Eli Lilly And Company	Substituted piperidines/piperazines as melanocortin receptor agonists
AU2002250343B2 (en)	2001-02-28	2006-05-25	Merck Sharp & Dohme Corp.	Acylated piperidine derivatives as melanocortin-4 receptor agonists
JP4323169B2 (ja)	2001-02-28	2009-09-02	メルクエンドカムパニーインコーポレーテッド	メラノコルチン−４受容体作働薬としてのアシル化ピペリジン誘導体
IL157253A0 (en)	2001-02-28	2004-02-19	Merck & Co Inc	Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1767525A1 (fr)	2001-04-09	2007-03-28	Novartis Vaccines and Diagnostics, Inc.	Composés guanidino comme agonistes du récepteur 4 de la mélanocortine (MC4-R)
US6911447B2 (en)	2001-04-25	2005-06-28	The Procter & Gamble Company	Melanocortin receptor ligands
US7115607B2 (en)	2001-07-25	2006-10-03	Amgen Inc.	Substituted piperazinyl amides and methods of use
US6977264B2 (en)	2001-07-25	2005-12-20	Amgen Inc.	Substituted piperidines and methods of use
US7160886B2 (en)	2003-03-03	2007-01-09	Merck & Co., Inc.	Acylated piperazine derivatives as melanocortin-4 receptor agonists
DE602004028228D1 (de)	2003-03-26	2010-09-02	Merck Sharp & Dohme	Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
US20050192286A1 (en)	2003-10-22	2005-09-01	Neurocrine Biosciences, Inc.	Ligands of melanocortin receptors and compositions and methods related thereto
JP4795965B2 (ja) *	2003-11-12	2011-10-19	エルジー・ライフ・サイエンシーズ・リミテッド	メラノコルチン受容体のアゴニスト
GB0402492D0 (en)	2004-02-04	2004-03-10	Pfizer Ltd	Pharmaceutically active compounds
JP2008506696A (ja)	2004-07-16	2008-03-06	メルク　エンド　カムパニー　インコーポレーテッド	メラノコルチン−４受容体作用薬としてのアシル化ピペリジン誘導体
JP2008506779A (ja)	2004-07-19	2008-03-06	メルク　エンド　カムパニー　インコーポレーテッド	メラノコルチン−４受容体作用薬としてのアシル化ピペリジン誘導体
DE102005000666B3 (de)	2005-01-04	2006-10-05	Sanofi-Aventis Deutschland Gmbh	Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1928460A2 (fr)	2005-08-01	2008-06-11	Pfizer Limited	Nouvelles utilisations de composes d'agonistes du recepteur de mc4
EP1912968A1 (fr)	2005-08-04	2008-04-23	Pfizer Limited	Composes piperidinoyl-pyrrolidine et piperidinoyl-piperidine
US8293900B2 (en)	2005-09-29	2012-10-23	Merck Sharp & Dohme Corp	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007041061A2 (fr)	2005-09-30	2007-04-12	Merck & Co., Inc.	Derives de piperidine acylee en tant qu'agonistes du recepteur de la melanocortine 4
CA2625877A1 (fr)	2005-10-18	2007-04-26	Merck & Co., Inc.	Derives de spiropiperidine acyles utilises en tant que modulateurs vis-a-vis du recepteur de melanocortine-4
JP2007131570A (ja)	2005-11-09	2007-05-31	Mitsubishi Pharma Corp	新規なアミノピロリジン誘導体
AP2008004602A0 (en)	2006-02-23	2008-10-31	Pfizer Ltd	Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2007096186A1 (fr)	2006-02-23	2007-08-30	Santhera Pharmaceuticals (Schweiz) Ag	Dérivés de phénylpipéridine substituée servant de modulateurs du récepteur de la mélanocortine-4.
EP2035373B1 (fr)	2006-06-09	2011-05-04	Action Pharma A/S	Dérivés de phényl pyrrole aminoguanidine
TWI332501B (en) *	2006-07-14	2010-11-01	Lg Life Sciences Ltd	Melanocortin receptor agonists
AU2007300529A1 (en)	2006-09-27	2008-04-03	Merck Sharp & Dohme Corp.	Acylated piperidine derivatives as melanocortin-4 receptor modulators
UA99555C2 (en) *	2008-11-12	2012-08-27	Элджи Лайф Саенсез Лтд.	Melanocortin receptor agonists

2009
- 2009-10-11 UA UAA201105960A patent/UA99555C2/ru unknown
- 2009-11-03 TW TW098137194A patent/TWI389903B/zh not_active IP Right Cessation
- 2009-11-10 AU AU2009314827A patent/AU2009314827B2/en active Active
- 2009-11-10 CA CA2742248A patent/CA2742248C/fr active Active
- 2009-11-10 MX MX2011004583A patent/MX2011004583A/es active IP Right Grant
- 2009-11-10 CN CN200980144988.6A patent/CN102282141B/zh active Active
- 2009-11-10 US US13/128,725 patent/US8288386B2/en active Active
- 2009-11-10 US US12/615,407 patent/US8039622B2/en active Active
- 2009-11-10 JP JP2011536237A patent/JP5399506B2/ja active Active
- 2009-11-10 NZ NZ592512A patent/NZ592512A/xx not_active IP Right Cessation
- 2009-11-10 GE GEAP2009012222 patent/GEP20135850B/en unknown
- 2009-11-10 PE PE2011000970A patent/PE20110684A1/es not_active Application Discontinuation
- 2009-11-10 WO PCT/KR2009/006568 patent/WO2010056022A2/fr not_active Ceased
- 2009-11-10 EA EA201170676A patent/EA019146B1/ru unknown
- 2009-11-10 EP EP09826254.6A patent/EP2350060B1/fr active Active
- 2009-11-10 BR BRPI0921063A patent/BRPI0921063B8/pt active IP Right Grant
- 2009-11-10 KR KR1020090108283A patent/KR101141976B1/ko active Active
- 2009-11-11 AR ARP090104355A patent/AR074109A1/es active IP Right Grant
- 2009-11-11 UY UY0001032238A patent/UY32238A/es not_active Application Discontinuation
2011
- 2011-04-26 IL IL212468A patent/IL212468A0/en unknown
- 2011-04-29 ZA ZA2011/03154A patent/ZA201103154B/en unknown
- 2011-05-03 EC EC2011011026A patent/ECSP11011026A/es unknown
- 2011-05-05 MA MA33818A patent/MA32774B1/fr unknown
- 2011-05-06 TN TN2011000222A patent/TN2011000222A1/fr unknown
- 2011-05-11 CO CO11057597A patent/CO6362006A2/es not_active Application Discontinuation
- 2011-05-12 CR CR20110250A patent/CR20110250A/es unknown
- 2011-05-12 CL CL2011001073A patent/CL2011001073A1/es unknown
- 2011-06-13 US US13/158,734 patent/US8236955B2/en active Active
- 2011-06-13 US US13/158,920 patent/US8183243B2/en active Active

Also Published As

Publication number	Publication date
BRPI0921063A2 (pt)	2015-08-25
EP2350060B1 (fr)	2013-09-18
UY32238A (es)	2010-01-05
US20110224219A1 (en)	2011-09-15
KR20100053458A (ko)	2010-05-20
AU2009314827A1 (en)	2010-05-20
AU2009314827B2 (en)	2012-04-05
MX2011004583A (es)	2011-06-01
US8039622B2 (en)	2011-10-18
US8236955B2 (en)	2012-08-07
CN102282141A (zh)	2011-12-14
US20110245500A1 (en)	2011-10-06
EP2350060A2 (fr)	2011-08-03
US8183243B2 (en)	2012-05-22
AR074109A1 (es)	2010-12-22
NZ592512A (en)	2012-12-21
JP2012508730A (ja)	2012-04-12
CA2742248A1 (fr)	2010-05-20
KR101141976B1 (ko)	2012-05-07
MA32774B1 (fr)	2011-11-01
CA2742248C (fr)	2014-01-14
EA019146B1 (ru)	2014-01-30
EA201170676A1 (ru)	2011-12-30
WO2010056022A3 (fr)	2010-09-10
BRPI0921063B8 (pt)	2021-05-25
GEP20135850B (en)	2013-06-10
UA99555C2 (en)	2012-08-27
WO2010056022A2 (fr)	2010-05-20
US20100120783A1 (en)	2010-05-13
TWI389903B (zh)	2013-03-21
PE20110684A1 (es)	2011-09-28
CL2011001073A1 (es)	2011-10-07
US8288386B2 (en)	2012-10-16
CO6362006A2 (es)	2012-01-20
JP5399506B2 (ja)	2014-01-29
BRPI0921063B1 (pt)	2021-03-16
CN102282141B (zh)	2014-09-10
CR20110250A (es)	2011-08-26
ZA201103154B (en)	2012-01-25
TW201022246A (en)	2010-06-16
US20110237795A1 (en)	2011-09-29
ECSP11011026A (es)	2011-06-30
EP2350060A4 (fr)	2012-07-25
IL212468A0 (en)	2011-06-30

Publication	Publication Date	Title
TN2011000222A1 (en)	2012-12-17	Melanocortin receptor agonists
WO2007098474A8 (fr)	2008-11-06	Composés de phényl-cycloalkyl contenant des structures à anneau hétérocyclique
WO2009098230A3 (fr)	2010-12-16	Mélanges pesticides
IN2012DN01241A (fr)	2015-05-15
PH12013502551A1 (en)	2015-11-06	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MY154909A (en)	2015-08-28	Novel thiophene derivatives
MY178894A (en)	2020-10-21	Therapeutic compositions containing macitentan
MX2013001493A (es)	2013-08-27	Composiciones orales que comprenden un compuesto de cinc y un agente anti-microbiano.
WO2012030927A3 (fr)	2012-09-27	Formes galéniques à libération modifiée d'agonistes de 5-ht2c, utiles pour la gestion du poids
MY149869A (en)	2013-10-31	Thiophene derivatives as s1p1/edg1 receptor agonists
ZA200807274B (en)	2009-11-25	Novel pyridine derivatives
PT2040755E (pt)	2011-07-08	Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
MX2009006304A (es)	2009-06-23	Nuevos compuestos de oxadiazol.
MX2010007807A (es)	2010-08-06	Mezclas de plaguicidas.
TW200942524A (en)	2009-10-16	Novel aminomethyl benzene derivatives
MX2010008177A (es)	2010-08-10	Mezclas de plaguicidas.
EA200970532A1 (ru)	2009-10-30	Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
TW200942530A (en)	2009-10-16	Pyridine compounds
MX2011008756A (es)	2011-09-09	Composicion insecticida que comprende un derivado de hidracida antranilica y un neonicotinoide.
EA201071395A1 (ru)	2011-06-30	Ингибитор толерантности к анальгетику
WO2012030957A3 (fr)	2012-07-12	Sels non hygroscopiques d'agonistes de 5-ht2c
WO2009098228A3 (fr)	2010-11-18	Mélanges pesticides
TW200639164A (en)	2006-11-16	Novel salt form of a dopamine agonist
MY160825A (en)	2017-03-31	Lanthionine derivatives
MX2009012761A (es)	2009-12-16	Neramexano para el tratamiento de nistagmo.